Adult

A former Navy pilot claims that a VA doctor misdiagnosed him with a mental disorder that prevented him from flying and ended his career. William Royster was told in 2004 that he was bipolar, that it was a permanent condition, and that he could no longer work in any capacity, according to the Navy Times. A different psychiatrist, however, later told Royster that he never met the criteria for diagnosis.

While a great deal of the excitement about advances in psychological treatments comes from the potential for research in neuroscience to unlock the secrets of the brain, many mental health experts would like to temper this enthusiasm. A special issue of the Behavior Therapist released this month calls into question the predominant conception of mental illnesses as brain disorders.

There is accumulating evidence that taking SSRI antidepressants increases the risk of bleeding and other complications during surgery, according to a review published in the British Journal of Anaesthesia.

The BBC reports that the number of people in Scotland taking antidepressants has increased by 5% in the past year with most of the patients being women and those in the poorest parts of the country. “We are now looking at the flabbergasting statistic of more than one in seven people in Scotland being prescribed antidepressants this year,” Conservative health spokesman Jackson Carlaw said. “We urgently have to look at better alternatives than simply parking people on medication in the hope things don't get any worse, with no aspiration for complete recovery."

One of psychiatry's most obvious vulnerabilities is the fact that various so-called antidepressant drugs induce homicidal and suicidal feelings and actions in some people, especially late adolescents and young adults. This fact is not in dispute, but psychiatry routinely downplays the risk, and insists that the benefits of these drugs outweigh any risks of actual violence that might exist.

Journalist Emma Reynolds profiles Amanda Waegeli, Ron Coleman, Nathan Grixli and Lyn Mahboub about their experiences coming to the Hearing Voices Network (HVN). HVN was established 10 years ago in Australia and provided a support group that encouraged people to listen to their voices rather than trying to block them out. The group now operates in 25 countries.

“Underscoring the incredible momentum to legalize marijuana is the misconception that the drug can’t hurt anybody,” Dr. Sushrut Jangi writes in the Boston Globe. “It can, especially young people.” He suggests that the biochemistry of marijuana effects "systems ordinarily involved in healthy behaviors like eating, learning and forming relationships” and “throws the finely tuned system off balance.”

The University of Minnesota recently announced that it is ending the controversial practice of recruiting study participants from patients involuntarily being held in their psychiatric unit. In a commentary for Minnesota’s Star Tribune, bioethicist and MIA contributor Carl Elliot reports that the university has still not apologized to the patient who spoke out against this practice. Instead, “the university has done its best to discredit him.”

Prior use of benzodiazepines, such as Xanax, Librium, or Ativan, may increase the risk of treatment-resistant depression (TRD), according to a new study published in The Journal of Nervous and Mental Disease.

A number of news outlets have been reporting on a review of modafinil, labeled the new "smart drug," this week. The review in question summarized the recent literature on the drug but others have claimed that the authors underestimated potential side-effects.

Medscape Psychiatry reports that the “man-made epidemic” of opioid abuse in the United States is the result of over-prescription and poor research.

With the explosion of genetic testing and the emerging field of pharmacogenetics, patients can now take a DNA test and receive psychiatric drug recommendations customized to fit their genetic makeup. In an editorial for the latest issue of the Journal of Nervous and Mental Disease, Columbia University Psychiatrist Robert Klitzman warns that clinicians need to be aware of the limitations of these genetic tests being marketed to them.

NBC News reports that "Genetic tests to identify the most effective psychiatry drugs are the hot new thing in the race to create personalized treatments based on people's DNA.” An investigation by the New England Center for Investigative Reporting, however, found that these new tests are based on small studies conducted by device manufacturers, and those with financial conflicts on interest.

The Guardian reports on the Recovery Bag Project, set up, “to provide solace and comfort to people experiencing mental health crises,” by self-described “mental health warrior” Polly Rogers.

NPR reports on how ketamine is being used off-label to treat depression.

While publication bias has been known to overestimate the efficacy of antidepressant treatments, a new study suggests that research on the use of psychotherapy in depression suffers from a similar bias.

The October edition of the Journal of World Psychiatry, the 3rd ranked journal of Psychiatry, will publish a reanalysis of antidepressant efficacy versus placebo in major depression. When the researchers, Arif Khan and Walter Brown, analyzed the data from the FDA archives for antidepressants approved between 1985 and 1997, “it was evident that the conventional wisdom of 70% response with antidepressants was at best an overestimate.” In fact, “the magnitude of symptom reduction was about 40% with antidepressants,” compared to “about 30% with placebo.”

Individuals diagnosed with psychotic disorders have an earlier onset of psychosis if they have previously been exposed to prescription stimulants, according to new research currently in press in the Journal of Psychiatric Research.

An article for the Los Angeles Times, entitled “His 83-year-old Wife jumped to her death from a Kaiser clinic- why?” tells the story of Barbara Ragan who stepped off a roof in front of her mental health clinic with traces of Xanax, Prozac and an antidepressant in her blood.

The University of Minnesota announced a change to its research ethics policies this month after coming under criticism “following the recruitment of a schizophrenia...

On Wednesday, JAMA Psychiatry released a meta-analysis comparing the results of cognitive-behavioral therapy and antidepressant medication in severely depressed populations. Currently, many practice guidelines suggest that antidepressants be used over psychotherapy for major depressive disorder. The analysis, however, found that “patients with more severe depression were no more likely to require medications to improve than patients with less severe depression.”

Let’s face it, as our kids slowly developing brains wrestle with behavioral and maturity issues while also trying to juggle expectations related to academic and social challenges, some of the behaviors they display can be quite concerning. Understandably, after trying what seems like everything in the books plus the kitchen, bathroom and laundry room sinks, caring and often exhausted parents are actively looking for help, resources and answers. But guess what? Without any need for pharmaceutical intervention or “drug therapy,” for centuries parents have been quite capable of helping challenged children overcome semi-annoying and concerning behaviors that some “experts” want to label today as symptoms of a mental disorder. Behaviors that a billion kids worldwide display every day.

Hundreds of people have been given remote control deep brain stimulation implants for psychiatric disorders such as depression, OCD and Tourette’s. Yet DBS specialists still have no clue about its mechanisms of action and research suggests its hefty health and safety risks far outweigh benefits.

Bloomberg reports that the FDA asked Pfizer in August “to modify safety warnings for its antidepressant Zoloft (sertraline) and acknowledge for the first time that some studies linked the mood-altering medication to heart defects in newborns.”

New research published in the July issue of The Journal of Clinical Psychiatry found that the use of mood stabilizers, antipsychotics, antidepressants, and hypnotics during pregnancy is associated with increased health risks to the infant.